Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie is expected to see continued strong growth in its immunology business, driven by strong script growth for Skyrizi and Rinvoq. However, the company faces pricing pressures that could negatively affect margins. Investor concerns regarding competition and potential LOEs are overblown, and their diverse portfolio and strong pipeline differentiate them from other pharmaceutical companies facing similar challenges.

Bears say

AbbVie is facing multiple risks that could negatively impact their financial performance and earnings growth, including increasing competition in the immunology market and potential negative pipeline trial results. The recent acquisitions of Cerevel and ImmunoGen may not be enough to offset any potential challenges in their base business. The company's high valuation and reliance on key products such as Skyrizi and Rinvoq also pose a risk if their market share is impacted.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $271.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $271.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.